These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32829931)

  • 1. Treatment for castration-resistant prostate cancer and drug interaction risk in polymedicated patients.
    Juárez Soto A
    Actas Urol Esp (Engl Ed); 2020 Dec; 44(10):641-643. PubMed ID: 32829931
    [No Abstract]   [Full Text] [Related]  

  • 2. Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer.
    Pilon D; Ellis LA; Xiao Y; Behl AS; Lefebvre P
    Am J Ther; 2019; 26(3):e422-e424. PubMed ID: 30677005
    [No Abstract]   [Full Text] [Related]  

  • 3. High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate.
    Jamani R; Lee EK; Berry SR; Saluja R; DeAngelis C; Giotis A; Emmenegger U
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1391-1399. PubMed ID: 27561266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-drug interaction potential in men treated with enzalutamide: Mind the gap.
    Benoist GE; van Oort IM; Smeenk S; Javad A; Somford DM; Burger DM; Mehra N; van Erp NP
    Br J Clin Pharmacol; 2018 Jan; 84(1):122-129. PubMed ID: 28881501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
    Aragon-Ching JB
    Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
    [No Abstract]   [Full Text] [Related]  

  • 6. ONECUT2 is a novel target for treatment of castration-resistant prostate cancer.
    Joglekar T; Lin J; Shibata M
    Expert Opin Ther Targets; 2020 Feb; 24(2):89-90. PubMed ID: 31983247
    [No Abstract]   [Full Text] [Related]  

  • 7. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
    Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibition in castration-resistant prostate cancer.
    Nappi L; Gleave ME
    Future Oncol; 2016 Mar; 12(5):577-80. PubMed ID: 26792387
    [No Abstract]   [Full Text] [Related]  

  • 9. [Updated treatment of castration-resistant prostate cancer].
    Xu S; Zhang ZY
    Zhonghua Nan Ke Xue; 2014 Dec; 20(12):1136-40. PubMed ID: 25597184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is it time for everolimus-based combination in castration-resistant prostate cancer?
    Roviello G; Ravelli A; Barni S; Petrelli F; Bottini A; Fox SB; Generali D
    Future Oncol; 2016 Aug; 12(16):1849-52. PubMed ID: 27250597
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA Approves First Treatment for Nonmetastatic, Castration-Resistant Prostate Cancer.
    Aschenbrenner DS
    Am J Nurs; 2018 Jun; 118(6):26. PubMed ID: 29794918
    [No Abstract]   [Full Text] [Related]  

  • 12. Enzalutamide in castration-resistant prostate cancer.
    Burki TK
    Lancet Oncol; 2014 Jul; 15(8):e312. PubMed ID: 25121180
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary.
    Stein CA
    Clin Genitourin Cancer; 2015 Oct; 13(5):407-9. PubMed ID: 26119230
    [No Abstract]   [Full Text] [Related]  

  • 14. Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer.
    Rhea LP; Gupta B; Aragon-Ching JB
    Asian J Androl; 2019; 21(2):107-108. PubMed ID: 30460933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leading causes of castration-resistant prostate cancer.
    Lu M; Lu H; Kong Q
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents for castration-resistant prostate cancer: Early experience and beyond.
    Fujimoto N
    Int J Urol; 2016 Feb; 23(2):114-21. PubMed ID: 26311471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabazitaxel for the therapy of metastatic castration-resistant prostate cancer in the aftermath of the CHAARTED trial.
    Pal SK; Sonpavde G
    BJU Int; 2015 Dec; 116(6):839-40. PubMed ID: 26542327
    [No Abstract]   [Full Text] [Related]  

  • 18. Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
    Sharp A; Welti J; Blagg J; de Bono JS
    Clin Cancer Res; 2016 Sep; 22(17):4280-2. PubMed ID: 27330057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug approval: Olaparib - metastatic castration-resistant prostate cancer with BRCA mutation].
    Saillant A; Flippot R
    Bull Cancer; 2021 Feb; 108(2):140-142. PubMed ID: 33546874
    [No Abstract]   [Full Text] [Related]  

  • 20. New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.
    Heidegger I; Heidenreich A; Pfister D
    Target Oncol; 2017 Feb; 12(1):37-45. PubMed ID: 27796762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.